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1314Objectives: Surgical resection is standard treatment for early-stage non–small cell lung cancer; however, per-
ception of postoperative risk may influence the decision to proceed for elderly patients. With population data, we
analyzed postoperative complications and morbidity predictors for older patients undergoing lobectomy for
stage I non–small cell lung cancer.
Methods: The Surveillance Epidemiology and End-Results–Medicare linked database (2000–2005) identified
patients (ages 66–80 years) undergoing lobectomy for stage I non–small cell lung cancer. We comprehensively
evaluated in-hospital postoperative complications (pulmonary, cardiac, infectious, noncardiopulmonary) with
International Classification of Diseases, Ninth Revision, diagnosis codes. Logistic regression models were con-
structed to identify patient, tumor, and treatment characteristics associated with complications.
Results: In all, 4171 patients were included, 2329 of whom had 4097 in-hospital postoperative complications
(55.8%). Pulmonary complications were most common (n ¼ 1598; 38.3%) followed by cardiac (n ¼ 1020;
24.5%). Complications were significantly associated with age at least 75 years, male sex, higher comorbidity
index, larger tumors, and treatment at nonteaching hospitals (P<.05). Patients with complications had a longer
median stay (8 days) than patients without (6 days; P<.001). The 30-day mortality was 4.2%.
Conclusions: Population-based analysis demonstrated that perioperative complications after lobectomy for
stage I non–small cell lung cancer in older patients exceeded 50% and were associated with specific patient,
tumor, and treatment characteristics. Better understanding of the impact of these risk factors may facilitate sur-
gical decision making and encourage implementation of more effective perioperative care guidelines for older
surgical patients. (J Thorac Cardiovasc Surg 2012;143:1314-23)Earn CME credits at
http://cme.ctsnetjournals.org
Postoperative complications are common among patients
undergoing surgical resection of non–small cell lung cancer
(NSCLC). Single-center studies from specialized cancer
treatment facilities and studies of data from voluntary re-
porting sources have published complication rates ranging
from 9% to 37%, with 30-day postoperative mortalities
of 3% or less for patients who undergo lobectomy for
NSCLC.1-3 Because these published data are based on
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The Journal of Thoracic and Cardiovascular Surthey likely reflect what can be expected when surgery is
performed by experienced participants—often with
advanced thoracic surgical training in higher-volume
centers—but may not accurately reflect the outcomes that
can be expected from modern, national practice patterns.
There is little doubt that anticipated postoperative morbid-
ity and its subsequent negative impact on quality of life influ-
ences surgical decision making, particularly for elderly
patients who may bemore likely to receive suboptimal onco-
logic therapy.4-7 Indeed, one study found that patients were
less likely to undergo surgical resection of early-stage lung
cancer if they believed that their overall quality of life would
be worse 1 year postoperatively8; this is despite the fact that
survey-based studies have shown little long-termnegative im-
pact on quality of life for selected patients older than 70 years
who undergo lobectomy.9,10 Thus a better understanding
of postoperative complication rates and the risk factors
associated with their development is of critical importance.
The median age of patients undergoing lobectomy in the
United States in 2006 was 68 years old1; as such, we recog-
nize a need to define surgical morbidity as precisely as possi-
ble and to identify the specific patient, tumor, and treatment
factors associated with the development of in-hospital post-
operative complications among elderly patients undergoing
surgical resection of NSCLC.gery c June 2012
Abbreviations and Acronyms
CI ¼ confidence interval
ICD-9 ¼ International Classification of
Diseases, Ninth Revision
ICD-
O3
¼ International Classification of
Diseases for Oncology, Third Edition
NSCLC ¼ non–small cell lung cancer
OR ¼ odds ratio
SEER ¼ Surveillance Epidemiology and End
Results
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SMATERIALS AND METHODS
Data Sources
We used the 2000 to 2005 Surveillance Epidemiology and End Results
(SEER)–Medicare database, a population-based set of cancer registries
encompassing approximately 26% of the US population11 linked to Medi-
care administrative data. SEER collects patient demographic information,
tumor characteristics, cancer treatment, and cancer survival data. For
patients who are Medicare eligible, linkage of the SEER–Medicare data
is performed by the National Cancer Institute and the Centers for Medicare
and Medicaid Services. The resulting database has successfully matched
93% of patients 65 years old and older within the SEER database with their
Medicare enrollment files, providing access to all covered outpatient, hos-
pital, physician, home health, and hospice claims.12
Study Cohort
We identified patients aged 66 to 80 years who had American Joint
Committee on Cancer13 stage I NSCLC diagnosed between 2000 and
2005 (Table 1). We included only patients with International Classification
of Diseases for Oncology, Third Edition (ICD-O3) histologic subtypes as
follows: adenocarcinoma, bronchoalveolar carcinoma, squamous cell car-
cinoma, and other NSCLC histologic types (see Appendix Table 1 for ICD-
O3 morphology codes).
Patients were excluded if they had a previous or subsequent cancer di-
agnosis; had the cancer diagnosis made by autopsy or death certificate; had
the cancer diagnosis listed in the rural Georgia, Alaska, or Louisiana (in
2005 only) registries; had nonoperative management according to to the
SEER database; underwent preoperative radiation; had an unknown month
of diagnosis; were enrolled in a managed care organization any time from 6
months before to 6 months after the cancer diagnosis (because Medicare
files do not include insurance claims data on managed care enrollees); or
were not enrolled in both Medicare Parts A and B. By applying these ex-
clusions, we created a cohort of patients with stage I NSCLC who under-
went surgery for their cancer and were also likely to have complete
claims within Medicare.
We then searched for hospitalization claims within 6 months of diagno-
sis for the remaining patients. Because lobectomy is the most appropriate
oncologic therapy for patients with stage I NSCLC with adequate func-
tional reserve,14,15 we included only those who were hospitalized for that
procedure and excluded patients who underwent only wedge resections
or segmental resections. We did include patients who underwent limited
resection (wedge resection or segmentectomy), provided they also
underwent subsequent definitive lobectomy within 6 months.Complications
We identified 53 individual, in-hospital postoperative complications ac-
cording to International Classification of Diseases, Ninth Revision (ICD-9)
diagnosis codes and classified them into the following 4 categories: (1)The Journal of Thoracic and Carthose patients who had a complication of any sort develop, (2) those who
had specifically pulmonary complications, (3) those who had specifically
cardiac complications, and (4) thosewho had specifically noncardiopulmo-
nary complications (see Appendix Table 1 for ICD-9 complication codes
used). We allowed patients to have multiple types of complications for
our analysis, all collected individually; an individual patients could there-
fore have pulmonary, cardiac, and noncardiopulmonary complications all
develop after the lobectomy. Because we used ICD-9 diagnosis codes,
the presence or absence of a complication was defined by the treating phy-
sician and subject to appropriate coding.
Variables
We evaluated potential confounding patient (age, sex, Charlson Comor-
bidity Index score, race), tumor (size, histologic type), and treatment
(treating facility, procedure type) characteristics. To measure patient co-
morbidities, we used the Charlson Comorbidity Index, which we scored
on the basis of information contained in hospitalization records from the
year before diagnosis. The Charlson Comorbidity Index is a validated mea-
sure of comorbid conditions; the measure assesses 19 conditions associated
with an increased risk of 1-year mortality among hospitalized patients.16
Use of Charlson Comorbidity Index within the SEER–Medicare database
has been demonstrated to predict mortality among patients with NSCLC.17
Statistical Analysis
Weconstructed logistic regressionmodels to identify the specificpatient,
tumor, and treatment characteristics that were associated with the develop-
ment of in-hospital postoperative complications in the 4 previously defined
categories (any, pulmonary, cardiac, and noncardiopulmonary). Tomeasure
the predictive ability of our multivariate models, we calculated the C statis-
tic for each. The C statistic is a measure of concordance between predicted
and observed responses. A value of 0.5 indicates no predictive ability of
a model, whereas a C statistic of 1 indicates perfect predictive ability, dem-
onstrating that all outcomes of interest are correctly identified by themodel.
Data were analyzed with SAS statistica software (version 9.1; SAS
Institute, Inc, Cary, NC). The University of Minnesota Institutional Review
Board: Human Subjects Committee determined that this study was exempt
from review under Code of Federal Regulations 45 part 46.101(b).
RESULTS
A total of 4171 patients underwent lobectomy for stage
I NSCLC between 2000 and 2005 and met all inclusion cri-
teria for the study. Most patients were older than 70 years
(n ¼ 3064; 73.4%); however, most had a low comorbidity
index (Charlson Comorbidity Index score of 0, n ¼ 3508;
73.6%; Table 2). We found no statistically significant dif-
ference in the proportion of patients aged 75 to 80 years
at diagnosis with a Charlson Comorbidity Index score
greater than 2 (13.2%) and that of patients aged 66 to 69
years at diagnosis (12.4%; P ¼ .31).
Overall, 63.4% of the patients in our study were treated
in teaching hospitals (university hospital or nonuniversity
teaching hospitals). There were no significant differences
between patients who were treated in teaching facilities
and those who were not according to age at diagnosis,
Charlson Comorbidity Index score, sex, histologic type,
or type of procedure (multiple vs single procedures;
P>.05 for all). Patients treated in teaching hospitals were
slightly more likely to be Asian (73% vs 62.7% of white
patients), and diagnosed with smaller tumors (64% of tu-
mors<2 cm vs 62% of tumors>5 cm; P ¼ .003).diovascular Surgery c Volume 143, Number 6 1315
TABLE 2. Patient demographic characteristics
No complications
(n ¼ 1842)
Any complication*
(n ¼ 2329)
P valueNo. % No. %
Age (y) .002
66–69 523 28.3% 584 25.1%
70–74 732 39.7% 886 38.1%
75–80 587 32.0% 859 36.9%
Sex .001
Male 794 43.2% 1184 50.8%
Female 1048 56.8% 1145 49.2%
Charlson Comorbidity Index .001
0 1454 78.9% 1617 69.4%
1 223 12.1% 357 15.3%
2 165 9.0% 355 15.3%
Race .78
White 1669 90.6% 2119 91.0%
Black 83 4.5% 107 4.6%
Other 90 4.9% 103 4.4%
Tumor size (cm) .006
<2 622 33.4% 691 29.7%
2 to<3 546 29.6% 693 29.8%
3 to<5 449 24.4% 630 27.0%
5 171 9.3% 263 11.3%
Unknown 54 2.9% 52 2.2%
Tumor histologic type .001
Adenocarcinoma 869 47.1% 973 41.8%
Squamous cell 547 29.7% 832 35.7%
Bronchoalveolar 288 15.7% 303 13.0%
Other 138 7.5% 221 9.5%
Teaching hospital .014
Yes 1206 65.6% 1439 61.8%
No 636 34.4% 890 38.2%
Procedure type .22
Lobectomy alone 1677 91.1% 2094 89.9%
>1 procedure 165 8.9% 235 10.1%
*In total, 2329 patients had 4097 complications.
TABLE 1. Delineation of final cohort
Excluded
Cumulative
cohort
Patient, tumor, and treatment criteria
Start:
Initial cohort
Stage I NSCLC patients aged>66 or<80 y
diagnosed 2000–2005
20,858
>1 Primary cancer diagnosis 7340 13,518
Diagnosis by autopsy, death certificate,
nursing home, or hospice records
24 13,494
Diagnosis made in rural Georgia,
Alaska, or Louisiana (2005 only)
187 13,307
Managed nonoperatively 4255 9052
Underwent surgical resection
less than lobectomy
1413 7639
Had preoperative radiation 99 7540
Unknown month of diagnosis 8 7532
Not hospitalized for surgery within
6 months of cancer diagnosis
715 6817
Medicare enrollment criteria
Not enrolled in Medicare parts A
and B 6 months before diagnosis
540 6277
Not enrolled in Medicare FFS 2106 4171
Final cohort 4171
All numbers represent numbers of patients. NSCLC, Non–small cell lung cancer;
FFS, fee for service.
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55.8%; 2329 patients had 4097 complications develop.
Specific complications by category are listed in Table 3.
Pulmonary complications developed in 38.3% of patients
and were the most common (1598 patients with 2174 pul-
monary complications), followed by cardiac complications
(1020 patients with 1086 cardiac complications). Atrial fi-
brillation was the most common single complication, occur-
ring in 22.7% of all patients and accounting for 87% of
cardiac complications. Noncardiopulmonary complications
(wound or surgical, hematologic, nonpneumonia infectious
disease, renal, and hepatic) developed in 20.1% of patients.
Thosewho had any complication develop had a significantly
longer median hospital stay (8 days) than did those without
complications (6 days; P<.001). The 30-day mortality was
4.2% (n ¼ 175) and did not vary significantly with age at
diagnosis (3.6% among 66- to 69-year-olds vs 5.0% among
75- to 80-year-olds; P ¼ .13). The 90-day mortality was
6.3% (n ¼ 261) and also did not vary significantly with
age at diagnosis (5.3% among 66- to 69-year-olds vs
7.0% among 75- to 80-year-olds; P ¼ .201).
Patients treated in teaching hospitals had lower
unadjusted rates of any complication (54.4%) than did
those treated at nonteaching hospitals (58.3%; P ¼ .01)
and lower unadjusted rates of pulmonary complications
(teaching, 36.2%, vs nonteaching, 42.0%; P¼ .002); how-
ever, there were no significant differences in cardiac or non-
cardiopulmonary complication rates according to type of1316 The Journal of Thoracic and Cardiovascular Surteaching institution. Thirty-day mortality (3.4% vs 5.6%;
P ¼ .008) and 90-day mortality (5.4% vs 7.8%;
P ¼ .001) were lower at teaching hospitals.
Multivariate Analyses
Results of the multivariate analysis evaluating the spe-
cific patient, tumor, and treatment characteristics associated
with the development of any in-hospital postoperative com-
plications are listed in Table 4. Complications were signif-
icantly more likely to occur among patients at least 75 years
old, male patients, those with a higher comorbidity index,
patients with larger tumors, patients with nonadenocarci-
noma tumor histologic type, and those who underwent sur-
gical treatment at nonteaching hospitals.
Tables 5 through 7 list the results of those same patient,
tumor, and treatment characteristics and their associations
with the development of specifically pulmonary, cardiac,gery c June 2012
TABLE 4. Predictors of complications (multivariate analysis
predicting any complication*)
Odds ratio 95% Confidence interval
Age (y)
66–69 1.00 Reference
70–74 1.09 0.94–1.28
75–80 1.31y 1.11–1.54
Sex
Female 1.00 Reference
Male 1.28y 1.13–1.46
Charlson Comorbidity Index
0 1.00 Reference
1 1.38y 1.15–1.66
2 1.83y 1.50–2.23
Race
White 1.00 Reference
Black 1.00 0.74–1.35
Other 0.98 0.73–1.32
Tumor size (cm)
<2 1.00 Reference
2 to<3 1.10 0.94–1.29
3 to<5 1.19y 1.00–1.40
5 1.26y 1.00–1.58
Tumor histologic type
Adenocarcinoma 1.00 Reference
Squamous cell 1.25 1.08–1.45
Bronchoalveolar 0.99 1.08–1.45
Other 1.42 1.12–1.79
Teaching hospital
Yes 1.00 Reference
No 1.16 1.02–1.32
Procedure type
Lobectomy only 1.00 Reference
>1 procedure 1.22 0.99–1.52
*C statistic ¼ 0.60. yP<.05.
TABLE 3. Pulmonary, cardiac, and noncardiopulmonary
complications (major complications separated by category)
Complication
occurrences
identified (no.)
Population with
complication (%)
Pulmonary* 2174 38.3%
Pneumothorax 705 16.9%
Atelectasis 525 12.6%
Pulmonary Insufficiency 253 6.1%
Respiratory failure 177 4.2%
Pneumonia 127 3.1%
Other 387 9.2%
Cardiacy 1,086 24.5%
Atrial fibrillation 946 22.7%
Acute myocardial
infarction
56 1.3%
Cardiac arrest 28 0.7%
Cerebrovascular accident 14 0.3%
Other 42 1.0%
Noncardiopulmonaryz 837 16.1%
Wound or surgical 300 7.2%
Nonpneumonia
infectious disease
216 5.2%
Hematologic 208 4.9%
Renal or hepatic 113 2.7%
*In total, 1598 patients had 2174 pulmonary complications. yIn total, 1020 patients
had 1086 cardiac complications. zIn total, 674 patients had 837 noncardiopulmonary
complications.
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Sand noncardiopulmonary complications, respectively. The
development of pulmonary complications was predicted by
the largest number of variables; interestingly, however,
neither older patient age nor tumor size was significantly
associated. Undergoing more than 1 pulmonary procedure
within 3 months did predict pulmonary complications (odds
ratio [OR], 1.29; 95% confidence interval [CI], 1.04–1.60),
as did patient sex, comorbidity index, tumor histologic type,
and surgery at a nonteaching hospital. Cardiac complications
were significantly associated only with patient variables
(age 70 years, male sex, comorbidity index, and race; all
P<.05) and were not predicted by any tumor or treatment
variables. Noncardiopulmonary complications were
predicted only by co-orbidity index and tumor histologic
type.
To summarize, age was a significant predictor for cardiac
complications only andwas not associatedwith the develop-
ment of pulmonary or noncardiopulmonary complications.
High Charlson Comorbidity Index score (2) was the only
variable significantly associated with the development of
complications in all 3 categories (pulmonary OR, 1.51;
95% CI, 1.25–1.83; cardiac OR, 1.57; 95% CI, 1.28–1.93;
noncardiopulmonary OR, 1.29; 95% CI, 1.02–1.65).
DISCUSSION
Postoperative morbidity and mortality after surgical re-
section of early-stage NSCLC continues to be a vexingThe Journal of Thoracic and Carproblem for thoracic oncologists. Despite the rates currently
reported by authors from established thoracic surgical
databases2 and cooperative multi-institutional data,1,18 we
demonstrated in this study that the national rate of
in-hospital postoperative complications actually exceeds
50% among patients older than 66 years. Similarly, we
found a 30-day mortality of 4.2% for this population, again
larger than previously reported in smaller studies including
younger patients. Importantly, we were able to identify
some of the critical patient, tumor, and treatment character-
istics that were associated with the development of compli-
cations in the early postoperative period. Such findings may
greatly aid clinicians in the identification of patients who
are more likely to have complications develop and may
serve as a guide for the implementation of better perioper-
ative care protocols designed to reduce postoperative mor-
bidity among elderly surgical patients.
These findings come at an important time in the care of
patients with cancer. Yu Greenblatt and colleagues19—
also with the SEER–Medicare database—found thatdiovascular Surgery c Volume 143, Number 6 1317
TABLE 5. Predictors of pulmonary complications (multivariate
analysis predicting any pulmonary complication*)
Odds ratio 95% Confidence interval
Age (y)
66–69 1.00 Reference
70–74 0.99 0.84–1.16
75–80 1.02 0.87–1.20
Sex
Female 1.00 Reference
Male 1.16y 1.02–1.32
Charlson Comorbidity Index
0 1.00 Reference
1 1.32y 1.10–1.59
2 1.51y 1.25–1.83
Race
White 1.00 Reference
Black 1.03 0.76–1.40
Other 0.99 0.73–1.34
Tumor size (cm)
<2 1.00 Reference
2 to<3 1.04 0.89–1.23
3 to<5 1.04 0.88–1.24
5 1.16 0.93–1.46
Tumor histologic type
Adenocarcinoma 1.00 Reference
Squamous cell 1.41y 1.21–1.63
Bronchoalveolar 0.92 1.21–1.63
Other 1.54y 1.22–1.94
Teaching hospital
Yes 1.00 Reference
No 1.27y 1.11–1.45
Procedure type
Lobectomy only 1.00 Reference
>1 procedure 1.29y 1.04–1.60
*C statistic ¼ 0.58. yP<.05.
TABLE 6. Predictors of cardiac complications (multivariate analysis
predicting any cardiac complication*)
Odds ratio 95% Confidence interval
Age (y)
66–69 1.00 Reference
70–74 1.29y 1.07–1.56
75–80 1.58y 1.31–1.91
Sex
Female 1.00 Reference
Male 1.46y 1.26–1.69
Charlson Comorbidity Index
0 1.00 Reference
1 1.36y 1.11–1.66
2 1.57y 1.28–1.93
Race
White 1.00 Reference
Black 0.78 0.54–1.12
Other 0.64y 0.43–0.95
Tumor size (cm)
<2 1.00 Reference
2 to<3 1.08 0.90–1.30
3 to<5 1.13 0.93–1.37
5 1.18 0.92–1.23
Tumor histologic type
Adenocarcinoma 1.00 Reference
Squamous 0.95 0.80–1.12
Bronchoalveolar 0.79y 0.63–0.99
Other 0.94 0.72–1.23
Teaching hospital
Yes 1.00 Reference
No 1.05 0.90–1.22
Procedure type
Lobectomy only 1.00 Reference
>1 procedure 1.00 0.78–1.28
*C statistic ¼ 0.59. yP<.05.
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dependent predictor of 1-year mortality. Similarly, we re-
cently demonstrated that the development of in-hospital
postoperative complications after surgery for stage I
NSCLC was an independent predictor of worse 5-year
cancer-specific survival among elderly patients.20 The re-
sults of such studies demonstrate that postoperative compli-
cations may have an impact on cancer survival long after the
original event. It is therefore critical to identify as precisely
as possible the distribution of postoperative complications
and to define the risk factors that are associated with their
development. Understanding the true distribution of com-
plications and the factors that predict them on the basis of
a well-established, national, population-based data set is
a crucial early step in establishing best practice care guide-
lines; such findings have the potential not only to improve
oncologic care for elderly patients acutely but to affect
long-term cancer survival as well.
Several factors likely contribute to the increased number
of postoperative complications and the higher mortality1318 The Journal of Thoracic and Cardiovascular Surseen in our study relative to other published studies. By us-
ing a national database, we have captured an older patient
population, nearly 2 thirds of whom were treated at non-
teaching institutions. It is likely that unmeasured and un-
available factors—such as thoracic surgical specialty
training, hospital volume, or patient selection—may be af-
fecting our data and contributing to the higher mortality. In
the Society for Thoracic Surgeons published database, the
mortality rate is 2.5% after pulmonary resection.2 It is
well known, however, that a large percentage of lung cancer
surgery is performed by nonthoracic surgeons.21 Addition-
ally, it is well established from published data that postop-
erative morbidity and mortality are significantly reduced
when oncologic and high-risk surgery is performed at
high-volume centers.22-24 The higher complication rate
observed in our study with population-based data has likely
captured a more accurate estimate of what can be expected
for modern practice patterns at the national level.
The older age of our population is likely another contrib-
uting factor to the higher complication rate in our study.gery c June 2012
TABLE 7. Predictors of noncardiopulmonary complications
(multivariate analysis predicting any noncardiopulmonary
complication*)
Odds ratio 95% Confidence interval
Age
66–69 1.00 Reference
70–74 1.17 0.95–1.46
75–80 1.19 0.96–1.48
Sex
Female 1.00 Reference
Male 1.16 0.98–1.37
Charlson Comorbidity Index
0 1.00 Reference
1 1.19 0.95–1.52
>2 1.29y 1.02–1.65
Race
White 1.00 Reference
Black 0.98 0.66–1.47
Other 1.41 0.98–2.03
Tumor size (cm)
<2 1.00 Reference
2 to<3 1.03 0.83–1.27
3 to<5 1.04 0.83–1.29
5 0.92 0.68–1.26
Tumor histologic type
Adenocarcinoma 1.00 Reference
Squamous cell 1.26y 1.04–1.53
Bronchoalveolar 1.13 0.87–1.46
Other 1.18 0.86–1.60
Teaching hospital
Yes 1.00 Reference
No 1.13 0.95–1.34
Procedure type
Lobectomy only 1.00 Reference
>1 procedure 1.11 0.84–1.46
*C statistic ¼ 0.59. yP<.05.
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SSwanson and colleagues18 reported a complication rate of
7.4% among patients recruited into the Cancer and Leuke-
mia Group B 39802 study that compared outcomes of
video-assisted thoracoscopic surgery versus open lobec-
tomy for early-stage NSCLC; the median age of patients
in that study was 66 years, with a range from 37 to 86 years.
Similarly, Allen and colleagues1 analyzed more than 1000
patients in the American College of Surgeons Oncology
Group Z0030 trial who underwent pulmonary resection
for NSCLC; the median age of patients in their study was
68 years (range, 23–89 years), with a complication rate of
38% and a postoperative mortality of 1.4%.
In this study, however, we focused specifically on cancer
surgery outcomes among patients older than 66 years,
knowing that the risk of perioperative complications in-
creases with increasing age. In a review of nearly 750 pa-
tients undergoing lobectomy for early-stage (IA) NSCLC,
Flores and colleagues25 found that the risk of development
of postoperative complications increased significantly withThe Journal of Thoracic and Carage. We similarly found that the risk of development of any
postoperative in-hospital complication was significantly in-
creased for patients older than 75 years; these patients were
1.3 times more likely to have a complication develop than
were patients 66 to 69 years old. Interestingly, though,
when we analyzed the patient risk factors associated with
the development of specific complications by category,
age was a significant predictor only of cardiac complica-
tions; age was not significantly associated with pulmonary
or noncardiopulmonary complications.
On the basis of the finding that older age at the time of lo-
bectomywas associated specificallywith the development of
cardiac complications but not pulmonary or noncardiopul-
monary complications, it is reasonable to advocate improved
preoperative assessment of cardiovascular fitness for elderly
patients with cancer diagnoses, as well as aggressive coun-
seling and lifestyle modification programs. Improvements
in patient care, both preoperatively and postoperatively,
may have the potential to reduce early, in-hospital postoper-
ative cardiac morbidity and to improve outcomes for long-
term lung cancer survivors. In a 2010 study of 22,518
patients with stage I NSCLC, we demonstrated that elderly
patients (aged 70–79 years) who survived for 7 years after
surgical resection of their disease were significantly more
likely to die of cardiovascular disease than of lung cancer.26
Such data support recent initiatives designed to enroll pa-
tients with NSCLC in supervised aerobic training programs
during the perioperative period,27,28 with the primary aim of
improving cardiovascular fitness and overall quality of life
and quite possibly even improving immediate surgical
outcomes and long-term patient survival. In light of the find-
ing that such programs have led to improvements in cardio-
pulmonary fitness and psychologic well being in other areas
of oncology,29 further research is needed specifically for pa-
tients undergoing pulmonary resection.
In addition to advanced age, we can further hypothesize
that our increased complication and mortality are a function
of specific treatment factors that are not available for anal-
ysis within the SEER–Medicare database. For example, the
presence or absence of thoracic surgical specialty training,
as well as specific hospital volume and experience, may par-
tially explain our results and is a very important inference
from our analysis. When specialty-trained thoracic sur-
geons perform lobectomies, a 2.5% complication rate can
be reasonably expected.2 A substantial proportion of lung
cancer surgery is performed by nonthoracic surgeons,21
however, which may have contributed to the higher compli-
cation rate we found when using a national, population-
based data set. Surgeon training and hospital volume are
not available for evaluation within the SEER database; in-
stead, we analyzed the impact of hospital setting on the de-
velopment of postoperative complications as a surrogate
measure. We found that being treated at a nonteaching hos-
pital (versus university hospitals and teaching nonuniversitydiovascular Surgery c Volume 143, Number 6 1319
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Shospitals) was associated with a significantly higher risk of
development of postoperative pulmonary complications.
We acknowledge that the status of a teaching institution is
not a perfect replacement for either surgeon training or hos-
pital volume; however, use of this variable as a proxy mea-
sure is consistent with other reports in thoracic (esophageal)
oncology,30 and it is the best variable currently available for
analysis.
The only characteristic that significantly predicted com-
plications within every category was the Charlson Comor-
bidity Index score. In a smaller, single-institution study of
205 patients undergoing surgical resection of NSCLC,
a Charlson Comorbidity Index grade of 3 or 4 was signifi-
cantly associated with adverse outcomes.31 In this evalua-
tion of a larger number of patients, we found that even
a lower grade (1 or 2) was a significant predictor of postop-
erative morbidity. The observation that nearly 75% of our
cohort had a Charlson Comorbidity Index score of 0 indi-
cates the general selection bias that occurs when surgeons
determine which elderly patients with early-stage NSCLC
are appropriate candidates for pulmonary resection.
Importantly, our finding that a patient’s composite co-
morbid status was the only variable that predicted postop-
erative complications of every category emphasizes the
need for surgeons to assess and understand as thoroughly
as possible the overall health status of elderly patients
when considering surgical resection of early-stage
NSCLC. By evaluating medical fitness—beyond the sin-
gle variable of advanced age—we may be better able to
identify patients at risk of development of postoperative
complications; subsequently, patients at elevated risk of
developing postoperative complications stand to benefit
greatly from the routine implementation of standardized
care algorithms designed to facilitate early rehabilitation
and hospital discharge. Perioperative measures, including
the use of thoracic epidural analgesia and early postoper-
ative ambulation, are examples of multidisciplinary inter-
ventions that can reduce complications after lobectomy.32
The results of our study may serve to aid in the identifica-
tion of those elderly patients most appropriate for targeted
use of these resources.
We acknowledge limitations to our analysis. From the
SEER database, we could not collect information regarding
the use of lymph node sampling versus lymph node dissec-
tion, nor were we able to collect information regarding the
use of video-assisted thoracoscopic surgery versus open sur-
gical technique. We are therefore unable to assess the ef-
fects, if any, that these factors have on the development of
complications. Additionally, more than 4000 patients were
excluded from this study because they did not undergo sur-
gical treatment, and among thosewho did have surgery, only
12.5% had a Charlson Comorbidity Index score of at least 2.
These points illustrate the effect that comorbid status had on
surgical patient selection; we thus have inherently studied1320 The Journal of Thoracic and Cardiovascular Surthe complication rate of a cohort of patients who were rela-
tively healthy at baseline and determined to be appropriate
candidates for surgical intervention. Finally, we analyzed
comorbidities as a composite score, rather than evaluating
individual diagnoses separately.
Despite these limitations, our study has several strengths.
SEER is a large database that allows the evaluation of large
numbers of patients. As such, the findings from this
database are more likely to be broadly reflective of current
practice patterns across the nation. Further, by using
Medicare-linked data, we were able to evaluate specific
complication codes for individuals and link their hospital
Medicare claims directly with their individual SEER demo-
graphic and treatment data, allowing a more robust analysis
of the effects that specific patient, tumor, and treatment vari-
ables had on the development of postoperative complica-
tions. The specific distribution of in-hospital postoperative
complications that we have provided here, along with a de-
tailed analysis of the factors that are most associated with
the development of complications among elderly patients
undergoing surgical resection of stage I NSCLC, may serve
to guide surgeons in appropriate patient selection. Further,
these findings may serve to stimulate the implementation
of perioperative protocols designed to reduce the incidence
of postoperative complications among elderly cancer pa-
tients. Given the recent finding that early postoperative
complications are associated with cancer survival,20 such
measures have the potential to improve not only acute out-
comes but long-term cancer survival as well.
This study used the linked SEER–Medicare database. The inter-
pretation and reporting of these data are our own sole responsibil-
ity. We acknowledge the efforts of the Applied Research Program,
National Cancer Institute; the Office of Research, Development
and Information, Centers for Medicare and Medicaid Services; In-
formationManagement Services, Inc; and the Surveillance, Epide-
miology, and End Results Program tumor registries in the creation
of the SEER–Medicare database.References
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APPENDIX TABLE 2. International Classification of Diseases, Ninth Revision, complication codes used
Code Explanation
Pulmonary
415.1 Pulmonary embolism (include all 415.1)
480 Viral pneumonia (include all 480.*)
481 Streptococcal pneumonia (include all 481.*)
482 Bacterial pneumonia (include all 482.*)
483 Other pneumonia (include all 483.*)
507.0 Aspiration pneumonia (include all 507.0*)
510 Empyema (include all 510.*)
511 Pleurisy and pleural effusion (include all 511.*)
512 Pneumothorax (include all 512.*)
513 Abscess of lung (include all 513.*)
518 Lung disease family
Include
518.0 Atelectasis
518.4 Acute pulmonary edema
518.5 Pulmonary insufficiency after surgery or trauma
518.7 Transfusion-related acute lung injury
518.81 Acute respiratory failure
518.82 Acute respiratory failure
Exclude
518 emphysemas include 518.1, 518.2, 518.3 only
518.6 Aspergillosis
518.8 Chronic respiratory failure; include 518.83, 518.84
518.89 Other
786.09 Respiratory distress or insufficiency not otherwise specified
786.3 Hemoptysis
799.1 Cardiorespiratory arrest (include all 799.1*)
997.31 Ventilator pneumonia
997.39 Pneumonia resulting from a procedure
Cardiac
410–411 Acute myocardial infarction (include all 410.* and 411.*)
420 Pericarditis (include all 420.*)
421 Endocarditis (include all 421.*)
427. 3 Atrial fibrillation or flutter (include all 427.3*)
427.5 Cardiac arrest
434 Occlusion of cerebral arteries (include all 434.* )
435 Transient cerebral ischemia (include all 435.*)
785.5 Shock, unspecified, nontraumatic (include all 785.5*)
798 Sudden death (include 798.1, 798.2, 798.9; exclude infant death, 798.0*)
997.02 Postoperative stroke or hemorrhage
Noncardiopulmonary
Nonpneumonia infectious disease
008.45 Infectious pseudomembranous colitis
038 Bacteremia or septecemia (include all 038.*)
599.0 Urinary tract infection (include all 599.0*)
790.7 Bacteremia not otherwise specified (include all 790.7*)
995.9 Systemic inflammatory response syndrome or sepsis (include all 995.9*)
998.0 Postoperative shock (include all 998.0*)
999.31 Infection due to central venous catheter
Hematologic
285.1 Blood loss anemia (include 285.1 only)
288.0 Neutropenia (include 288.00, 288.03, 288.04, 288.09; exclude 288.01, 288.02)
444.2 Arterial embolism of extremities (include all 444.2*)
451 Thrombophlebitis (include all 451.*)
453 Acute venous embolism extremity (include all 453.4*, 453.6*, 453.8*, 453.9*; exclude all 453.5*, 453.7*)
(Continued)
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APPENDIX TABLE 2. Continued
Code Explanation
Renal
584 Acute kidney failure (include all 584.0–584.9)
586 Renal failure not otherwise specified (include all 586.*)
Hepatic
570 Liver failure (include all 570.0–570.9)
Wound and surgical
998.1 Hemorrhage, hematoma, seroma complicating a procedure (include all 998.1*)
998.2 Iatrogenic or accidental puncture during a procedure (organ or vessel)
998.3 Disruption of a wound
998.4 Foreign body accidently left in a wound
998.5 Postoperative infection of wound or seroma
998.8 Postoperative subcutaneous emphysema, a nonhealing wound, or complication not otherwise specified
999.1 Air embolism
*Wild card indicates inclusion of all numbered subtypes.
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